Lite Strategy (LITS) Current Deferred Revenue (2016 - 2023)
Lite Strategy (LITS) posted quarterly Current Deferred Revenue of $64.5 million for Q2 2023, up 1234.3% year-over-year from $4.8 million in Q2 2022, and up 3974.54% quarter-over-quarter from $1.6 million in Q1 2023.
Lite Strategy (LITS) Current Deferred Revenue (2016 - 2023) Analysis & Trends
Lite Strategy's Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $64.5 million for Q2 2023.
- In Q2 2023, Current Deferred Revenue rose 1234.3% year-over-year to $64.5 million; the TTM figure through Jun 2023 stood at $64.5 million (up 1234.3% YoY), while the FY2023 annual figure was $64.5 million, up 1234.3% from the prior year.
- Current Deferred Revenue for Q2 2023 stood at $64.5 million, up from $1.6 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $64.5 million in Q2 2023, with the low at $1.6 million in Q1 2023.
- The 5-year median for Current Deferred Revenue is $4.7 million (2022), against an average of $12.8 million.
- Peak annual rise in Current Deferred Revenue reached 1234.3% in 2023, while the deepest fall reached 95.08% in 2023.
- Lite Strategy's Current Deferred Revenue stood at $3.1 million in 2019, then soared by 39.2% to $4.3 million in 2020, then soared by 685.45% to $33.4 million in 2021, then tumbled by 91.33% to $2.9 million in 2022, then jumped by 2126.44% to $64.5 million in 2023.
- Business Quant data shows LITS's Current Deferred Revenue at $64.5 million in Q2 2023, $1.6 million in Q1 2023, and $2.9 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 64.50 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Dec 31, 2022 | 2.90 Mn |
| Sep 30, 2022 | 4.50 Mn |
| Jun 30, 2022 | 4.83 Mn |
| Mar 31, 2022 | 32.16 Mn |
| Dec 31, 2021 | 33.41 Mn |
| Sep 30, 2021 | 35.09 Mn |
| Jun 30, 2021 | 14.68 Mn |
| Mar 31, 2021 | 4.08 Mn |
| Dec 31, 2020 | 4.25 Mn |
| Sep 30, 2020 | 5.21 Mn |
| Jun 30, 2020 | 5.23 Mn |
| Mar 31, 2020 | 2.48 Mn |
| Dec 31, 2019 | 3.06 Mn |
| Sep 30, 2019 | 3.68 Mn |
| Jun 30, 2019 | 4.96 Mn |
| Mar 31, 2019 | 4.20 Mn |
| Dec 31, 2018 | 3.98 Mn |
| Sep 30, 2018 | 740,000.00 |